These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 26671986)
1. The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. Tanboon J; Williams EA; Louis DN J Neuropathol Exp Neurol; 2016 Jan; 75(1):4-18. PubMed ID: 26671986 [TBL] [Abstract][Full Text] [Related]
2. Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers. Nakao T; Sasagawa Y; Nobusawa S; Takabatake Y; Sabit H; Kinoshita M; Miyashita K; Hayashi Y; Yokoo H; Nakada M Brain Tumor Pathol; 2017 Oct; 34(4):149-154. PubMed ID: 28795231 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Brandner S; von Deimling A Neuropathol Appl Neurobiol; 2015 Oct; 41(6):694-720. PubMed ID: 25944653 [TBL] [Abstract][Full Text] [Related]
4. The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features. Cykowski MD; Allen RA; Kanaly AC; Fung KM; Marshall R; Perry A; Stolzenberg ED; Dunn ST J Neurooncol; 2013 Dec; 115(3):477-86. PubMed ID: 24057326 [TBL] [Abstract][Full Text] [Related]
5. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Karsy M; Guan J; Cohen AL; Jensen RL; Colman H Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343 [TBL] [Abstract][Full Text] [Related]
6. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
8. The efficacy of immunohistochemistry in the diagnosis of molecular genetic alterations in central nervous system gliomas: Next-generation sequencing of 212 mutations in 112 patients. Daoud EV; Chkheidze R; Yell PC; Hatanpaa KJ; Raisanen JM; Cai C Clin Neuropathol; 2022; 41(1):35-40. PubMed ID: 34672256 [TBL] [Abstract][Full Text] [Related]
9. Biomarker-driven diagnosis of diffuse gliomas. Appin CL; Brat DJ Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic markers in gliomas - an update. Ma R; de Pennington N; Hofer M; Blesing C; Stacey R Br J Neurosurg; 2013 Jun; 27(3):311-5. PubMed ID: 23278177 [TBL] [Abstract][Full Text] [Related]
11. Clinical impact of molecular biomarkers in gliomas. Siegal T J Clin Neurosci; 2015 Mar; 22(3):437-44. PubMed ID: 25533211 [TBL] [Abstract][Full Text] [Related]
12. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas. Malueka RG; Theresia E; Fitria F; Argo IW; Donurizki AD; Shaleh S; Innayah MR; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA; Dwianingsih EK Asian Pac J Cancer Prev; 2020 Nov; 21(11):3229-3234. PubMed ID: 33247679 [TBL] [Abstract][Full Text] [Related]
15. BRAF Wang W; Wang M; Jiang H; Wang T; Da R BMC Neurol; 2021 May; 21(1):195. PubMed ID: 33980169 [TBL] [Abstract][Full Text] [Related]
16. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing. Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305 [TBL] [Abstract][Full Text] [Related]
17. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690 [TBL] [Abstract][Full Text] [Related]
18. Comparison of immunohistochemistry and DNA sequencing for the detection of IDH1 mutations in gliomas. Zou Y; Bai HX; Wang Z; Yang L Neuro Oncol; 2015 Mar; 17(3):477-8. PubMed ID: 25556921 [No Abstract] [Full Text] [Related]
19. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]